Immune response to haptenized tumor antigen as possible mechanism of anticancer action of hypoxic bioreductive agents at low doses

Результат исследований: Материалы для журналаОбзорная статья

6 Цитирования (Scopus)

Выдержка

Possible anticancer effect mechanism of hypoxic bioreductive agents (HBA) at low nongenotoxic doses are reviewed. Experimental and clinical investigations show the process which can develop step-by-step when injecting HBA into the tumor-bearing organism resulting in the stimulation of antitumor immunity: HBA activation in hypoxic tumor tissue, conjugation of activated HBA with proteins of tumor cells, antigen processing, presentation of neoantigen epitops in association with major histocompatibility complex-I and cytolysis of these tumor cells by T-killers. The present process can be a variant of the delayed-type hypersensitivity reaction in the tumor region. The direct regulating influence of HBA on immunocompetent and/or tumor cells as a result of interaction of these drugs with superficial or intercellular receptors is supposed to be realized additively with this process. It is concluded that the ability of HBA to selective activation in tumor tissue and formation of immunogenic conjugates with tumor proteins can be a starting- point for developing drugs with immunomodulation anticancer properties.

Язык оригиналаАнглийский
Страницы (с-по)291-296
Число страниц6
ЖурналCancer Biotherapy and Radiopharmaceuticals
Том14
Номер выпуска4
СостояниеОпубликовано - 1999
Опубликовано для внешнего пользованияДа

Отпечаток

Neoplasm Antigens
Neoplasms
Antigen Presentation
Immunomodulation
Delayed Hypersensitivity
Major Histocompatibility Complex
Drug Interactions
Immunity
Proteins
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Цитировать

Immune response to haptenized tumor antigen as possible mechanism of anticancer action of hypoxic bioreductive agents at low doses. / Schepetkin, Igor.

В: Cancer Biotherapy and Radiopharmaceuticals, Том 14, № 4, 1999, стр. 291-296.

Результат исследований: Материалы для журналаОбзорная статья

@article{66f54a4503904179a4e78a79143912ff,
title = "Immune response to haptenized tumor antigen as possible mechanism of anticancer action of hypoxic bioreductive agents at low doses",
abstract = "Possible anticancer effect mechanism of hypoxic bioreductive agents (HBA) at low nongenotoxic doses are reviewed. Experimental and clinical investigations show the process which can develop step-by-step when injecting HBA into the tumor-bearing organism resulting in the stimulation of antitumor immunity: HBA activation in hypoxic tumor tissue, conjugation of activated HBA with proteins of tumor cells, antigen processing, presentation of neoantigen epitops in association with major histocompatibility complex-I and cytolysis of these tumor cells by T-killers. The present process can be a variant of the delayed-type hypersensitivity reaction in the tumor region. The direct regulating influence of HBA on immunocompetent and/or tumor cells as a result of interaction of these drugs with superficial or intercellular receptors is supposed to be realized additively with this process. It is concluded that the ability of HBA to selective activation in tumor tissue and formation of immunogenic conjugates with tumor proteins can be a starting- point for developing drugs with immunomodulation anticancer properties.",
keywords = "Bioreductive agent, Delayed-type hypersensitivity reaction, Hapten-modified tumor antigen, Hypoxia, Low-dose anticancer chemotherapy, Radiosensitizer",
author = "Igor Schepetkin",
year = "1999",
language = "English",
volume = "14",
pages = "291--296",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Immune response to haptenized tumor antigen as possible mechanism of anticancer action of hypoxic bioreductive agents at low doses

AU - Schepetkin, Igor

PY - 1999

Y1 - 1999

N2 - Possible anticancer effect mechanism of hypoxic bioreductive agents (HBA) at low nongenotoxic doses are reviewed. Experimental and clinical investigations show the process which can develop step-by-step when injecting HBA into the tumor-bearing organism resulting in the stimulation of antitumor immunity: HBA activation in hypoxic tumor tissue, conjugation of activated HBA with proteins of tumor cells, antigen processing, presentation of neoantigen epitops in association with major histocompatibility complex-I and cytolysis of these tumor cells by T-killers. The present process can be a variant of the delayed-type hypersensitivity reaction in the tumor region. The direct regulating influence of HBA on immunocompetent and/or tumor cells as a result of interaction of these drugs with superficial or intercellular receptors is supposed to be realized additively with this process. It is concluded that the ability of HBA to selective activation in tumor tissue and formation of immunogenic conjugates with tumor proteins can be a starting- point for developing drugs with immunomodulation anticancer properties.

AB - Possible anticancer effect mechanism of hypoxic bioreductive agents (HBA) at low nongenotoxic doses are reviewed. Experimental and clinical investigations show the process which can develop step-by-step when injecting HBA into the tumor-bearing organism resulting in the stimulation of antitumor immunity: HBA activation in hypoxic tumor tissue, conjugation of activated HBA with proteins of tumor cells, antigen processing, presentation of neoantigen epitops in association with major histocompatibility complex-I and cytolysis of these tumor cells by T-killers. The present process can be a variant of the delayed-type hypersensitivity reaction in the tumor region. The direct regulating influence of HBA on immunocompetent and/or tumor cells as a result of interaction of these drugs with superficial or intercellular receptors is supposed to be realized additively with this process. It is concluded that the ability of HBA to selective activation in tumor tissue and formation of immunogenic conjugates with tumor proteins can be a starting- point for developing drugs with immunomodulation anticancer properties.

KW - Bioreductive agent

KW - Delayed-type hypersensitivity reaction

KW - Hapten-modified tumor antigen

KW - Hypoxia

KW - Low-dose anticancer chemotherapy

KW - Radiosensitizer

UR - http://www.scopus.com/inward/record.url?scp=0032766009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032766009&partnerID=8YFLogxK

M3 - Review article

C2 - 10850314

AN - SCOPUS:0032766009

VL - 14

SP - 291

EP - 296

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 4

ER -